# Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

> **NCT01080209** · PHASE2 · COMPLETED · sponsor: **Allergan** · enrollment: 215 (actual)

## Conditions studied

- Patients Who Participated in an Intravitreal Brimo PS DDS® Study

## Interventions

- **DRUG:** Brimo PS DDS®
- **OTHER:** Sham

## Key facts

- **NCT ID:** NCT01080209
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2015-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01080209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01080209, "Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01080209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*